Rosalind Advisors, Inc.
An institutional investment manager in TORONTO. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1622627.
- Reported value$269.2m
- Positions35
Holdings: 35 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Delcath Systems, Inc.DCTH | COM NEW | 24661P807 | 41.6 | 15.4% | 3,300,389 | Unchanged | |
| Fennec Pharmaceuticals IncFENC | COM | 31447P100 | 34.3 | 12.7% | 3,188,001 | Added+279,800 | |
| Xeris Biopharma Holdings IncXERS | COM | 98422E103 | 23.0 | 8.6% | 2,908,981 | Reduced−322,719 | |
| Savara IncSVRA | COM | 805111101 | 19.6 | 7.3% | 3,178,121 | Reduced−25,600 | |
| Verastem IncVSTM | COM NEW | 92337C203 | 15.2 | 5.7% | 3,986,509 | Added+1,848,034 | |
| X4 Pharmaceuticals IncXFOR | COM NEW | 98420X202 | 15.0 | 5.6% | 3,214,766 | Unchanged | |
| Eyepoint Pharmaceuticals IncEYPT | COM NEW | 30233G209 | 14.1 | 5.2% | 988,230 | Reduced−48,507 | |
| Cybin Inc | COM NEW | 23256X407 | 12.9 | 4.8% | 1,956,814 | Added+425,000 | |
| VOR Biopharma IncVOR | COM NEW | 929033207 | 11.9 | 4.4% | 648,600 | Reduced−51,400 | |
| Vaxcyte IncPCVX | COM | 92243G108 | 11.6 | 4.3% | 200,000 | Reduced−90,000 | |
| Mediwound Ltd | SHS NEW | M68830112 | 11.0 | 4.1% | 749,054 | Unchanged | |
| Celldex Therapeutics IncCLDX | COM NEW | 15117B202 | 7.4 | 2.8% | 200,000 | Reduced−130,000 | |
| Biocryst Pharmaceuticals IncBCRX | COM | 09058V103 | 7.2 | 2.7% | 721,504 | Reduced−201,553 | |
| Profound Medical CorpPROF | COM NEW | 74319B502 | 5.5 | 2.0% | 828,118 | Unchanged | |
| Talphera IncTLPH | COM NEW | 00444T209 | 5.3 | 2.0% | 5,169,501 | Added+1,815,585 | |
| Atea Pharmaceuticals IncAVIR | COM | 04683R106 | 5.0 | 1.8% | 1,070,550 | Reduced−101,305 | |
| Myomo IncMYO | COM NEW | 62857J201 | 3.8 | 1.4% | 3,637,886 | Reduced−209,386 | |
| Ovid Therapeutics IncOVID | COM | 690469101 | 3.0 | 1.1% | 1,107,994 | Unchanged | |
| Neuraxis IncNRXS | COM | 64134X201 | 3.0 | 1.1% | 508,055 | Added+221,917 | |
| Abivax SAABVX | SPONSORED ADS | 00370M103 | 2.8 | 1.0% | 20,869 | New+20,869 | |
| Inspiremd IncNSPR | COM | 45779A846 | 2.7 | 1.0% | 3,905,743 | Unchanged | |
| Regentis Biomaterials Ltd | ORDINARY SHARES | M8211G108 | 2.5 | 0.9% | 701,685 | Added+450,175 | |
| Sellas Life Sciences Group Inc | PUT | 81642T959 | 2.3 | 0.9% | 568,700 | Put | New+568,700 |
| Polypid Ltd | COM | M8001Q126 | 2.0 | 0.7% | 389,455 | Reduced−208,471 | |
| Biofrontera IncBFRI | COM NEW | 09077D209 | 1.2 | 0.4% | 1,275,609 | Added+111,647 | |
| Kura Oncology IncKURA | COM | 50127T109 | 1.1 | 0.4% | 100,000 | Unchanged | |
| Spruce Biosciences IncSPRB | COM NEW | 85209E208 | 1.1 | 0.4% | 20,000 | New+20,000 | |
| Aquestive Therapeutics IncAQST | COM | 03843E104 | 1.0 | 0.4% | 250,000 | Unchanged | |
| Onkure Therapeutics IncOKUR | COM CL A | 68277Q105 | 0.7 | 0.3% | 150,000 | Reduced−293,763 | |
| Pepgen IncPEPG | COM | 713317105 | 0.6 | 0.2% | 350,000 | New+350,000 | |
| CG Oncology Inc | CALL | 156944900 | 0.4 | 0.1% | 31,000 | Call | New+31,000 |
| Eyepoint Pharmaceuticals Inc | CALL | 30233G909 | 0.1 | <0.1% | 50,300 | Call | New+50,300 |
| Ishares TR | PUT | 464287955 | 0.1 | <0.1% | 500,000 | Put | New+500,000 |
| SPDR Series Trust | PUT | 78464A950 | 0.0 | <0.1% | 140,600 | Put | New+140,600 |
| Tenax Therapeutics Inc | PUT | 88032L955 | 0.0 | <0.1% | 6,200 | Put | New+6,200 |
Sold out: 12 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Annexon IncANNX | COM | 03589W102 | 0.0 | 0.0% | 0 | Sold out−200,000 | |
| Arrivent Biopharma Inc | CALL | 04272N902 | 0.0 | 0.0% | 0 | Call | Sold out−108,900 |
| Avalo Therapeutics IncAVTX | COM NEW | 05338F306 | 0.0 | 0.0% | 0 | Sold out−75,000 | |
| CG Oncology IncCGON | COM | 156944100 | 0.0 | 0.0% | 0 | Sold out−100,000 | |
| Definium Therapeutics IncDFTX | COM SHS | 24477V105 | 0.0 | 0.0% | 0 | Sold out−125,000 | |
| Invesco QQQ TR | PUT | 46090E953 | 0.0 | 0.0% | 0 | Put | Sold out−250,000 |
| Lipocine IncLPCN | COM NEW | 53630X203 | 0.0 | 0.0% | 0 | Sold out−221,616 | |
| Replimune Group Inc | CALL | 76029N906 | 0.0 | 0.0% | 0 | Call | Sold out−1,275,600 |
| SPDR S&P 500 ETF TR | PUT | 78462F953 | 0.0 | 0.0% | 0 | Put | Sold out−125,000 |
| Uniqure NV | CALL | N90064901 | 0.0 | 0.0% | 0 | Call | Sold out−295,800 |
| Viridian Therapeutics Inc | PUT | 92790C954 | 0.0 | 0.0% | 0 | Put | Sold out−263,600 |
| Viridian Therapeutics IncVRDN | COM | 92790C104 | 0.0 | 0.0% | 0 | Sold out−250,401 |
Source: SEC EDGAR, Form 13F-HR, accession 0001622627-26-000022 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.